ScripBiopharmaceutical companies raised just $13.1bn during the first quarter of 2025 – less than half of the $30.1bn raised in Q1 of 2024, the latest Financing Quarterly Statistics report from Biomedtra
Pink SheetThe regenerative medicine sector continues to seek increased contact with the US Food and Drug Administration, even as the architects of the Center for Biologics Evaluation and Research review structu
ScripNeurocrine Updates On Crenessity Launch Neurocrine Biosciences announced encouraging early sales for its new commercial product, Crenessity (crinecerfont), in its first full quarter of launch. Crene
Pink SheetReforming the US Food and Drug Administration has value, but the Trump Administration’s recent layoffs and other changes have been crudely implemented and are insulting to staff, one biotech CEO said,